Daily non-political popular news in brief.
Additional hormone therapy use after radiation for some prostate cancers extends survival
11-06-2006 · EurekAlert!The largest study examining the benefits of long-term use of hormone therapy after radiation treatment for prostate cancer shows men with aggressive locally advanced disease live longer if hormones are used for an additional 24 months. Research also showed other significant benefits for those with less aggressive cancers who receive hormones.
Read more »
Keywords: additional, hormone, therapy, radiation, prostate, cancers, extends, survival, cancer, extend
« Previous | Next »
Similar news on "Additional hormone therapy use after radiation for some prostate cancers extends survival":
- Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
01-02-2008 · EurekAlert!
Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years -- especially the development of bone metastases -- and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.
Similar news · Read more »
- Combination therapy improves survival for certain prostate cancer patients
01-22-2008 · EurekAlert!
Men with localized prostate cancer who were treated with male hormone suppression therapy and radiation treatment had longer survival, but those with moderate to high levels of other illnesses did not experience this effect, according to a study in the Jan. 23 issue of JAMA.
Similar news · Read more »
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit
11-14-2006 · EurekAlert!
Treating advanced prostate cancer with radiation therapy after removal of the prostate gland reduces the risk of disease recurrence, but does not appear to significantly improve the length of survival, according to a study in the Nov. 15 issue of JAMA, a theme issue on men's health.
Similar news · Read more »
- New classification better identifies prostate cancer patients to benefit from hormone therapy
11-08-2006 · EurekAlert!
A new classification system for evaluating men after radiation treatment for prostate cancer better determines which men may recur and thus may benefit from hormone therapy. Doctors applied the new system to 1,831 previously treated patients. The new classification could alter the course of treatment, which may include hormone therapy sooner and for more men. The study demonstrates a significant improvement in predicting endpoints, including distant metastasis, cause-specific mortality and overall mortality.
Similar news · Read more »
- New research disproves belief that group psychotherapy extends the lives of cancer patients
05-01-2007 · EurekAlert!
Previously-published research has given credence to the notion that psychotherapy extends the lives of people with cancer. In fact, one in four cancer patients believe that science supports the idea that participating in group therapy will extend their lives. However, researchers as the University of Pennsylvania School of Medicine concluded -- after an extensive research review -- that there is no compelling evidence linking psychotherapy or support groups with survival among cancer patients.
Similar news · Read more »
- More than 6 months of hormone therapy doesn't help prostate cancer patients live longer
11-05-2006 · EurekAlert!
Prostate cancer patients treated with either radiation or surgery who use hormone therapy for longer than six months do not survive any longer than patients who use the treatment for a shorter amount of time, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Similar news · Read more »
- Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
12-31-2007 · EurekAlert!
Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.
Similar news · Read more »
- Higher doses of radiation for prostate cancer do not decrease sexual function
10-29-2007 · EurekAlert!
Recent advances in the delivery of radiation therapy for prostate cancer are fueling a new trend of providing higher radiation doses over shorter periods of time. But does the daily increase in radiation lead to more sexual dysfunction than the conventional dose? New research by physicians at Fox Chase Cancer Center says it does not.
Similar news · Read more »
- Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
10-23-2006 · EurekAlert!
While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Tthe study's authors say potential improvement in cancer-free survival beyond five years with the added therapy may be less than two percent for most patients.
Similar news · Read more »
- Microarray provides 3 genomic guides to breast cancer treatment decisions
09-06-2007 · EurekAlert!
Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment, and the cancer's vulnerability to chemotherapy or hormone therapy, researchers at the University of Texas M. D. Anderson Cancer Center report at the first American Society of Clinical Oncology ASCO Breast Cancer Symposium, Sept. 7-8, in San Francisco.
Similar news · Read more »
